Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Rethinking Blockbuster Model After Exanta “Not Approvable”

Executive Summary

FDA's "not approvable" decision for AstraZeneca's Exanta highlights the increasing difficulty of developing drugs with blockbuster potential while satisfying strict regulatory standards

You may also be interested in...



Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa

When FDA's Cardiovascular and Renal Drugs Advisory Committee meets Sept. 20 to consider Boehringer Ingelheim's Pradaxa (dabigatran) for stroke prevention, a significantly higher rate of heart attacks among clinical trial patients compared with warfarin is likely to come up.

J&J’s Xarelto Wins Favorable Committee Vote, But Will FDA Delay Approval For ATLAS Data?

Cedars-Sinai cardiologist Kaul and Public Citizen’s Wolfe are the two "no" votes in 15-2 panel nod for the anti-coagulant.

Drug-Induced Liver Injury Workshop Offers More Questions Than Answers

To fully understand an experimental drug's potential for liver toxicity, clinical trials should be better designed to reflect real-world populations, including patients with liver disease, but neither FDA nor experts from industry and academia at a recent workshop on the topic were able to provide many answers on how to do so safely

Related Content

UsernamePublicRestriction

Register

PS044823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel